When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
VBLT - Dosing underway in VBL Therapeutics' VB-201 mid-stage study in COVID-19
Vascular Biogenics Ltd.
VBL Therapeutics (VBLT) has dosed the first patient in a randomized controlled Phase 2 study evaluating VB-201 for the treatment of COVID-19. The study will assess the ability of VB-201 to prevent clinical deterioration and reduce morbidity and mortality in patients with severe COVID-19.Studied in over 600 subjects, VB-201 previously demonstrated proof of concept in a Phase 2 study in vascular inflammation, meeting the primary endpoint of the trial.